Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Dev Biol ; 461(1): 86-95, 2020 05 01.
Article in English | MEDLINE | ID: mdl-31982375

ABSTRACT

One of the main obstacles for studying the molecular and cellular mechanisms underlying human neurodevelopment in vivo is the scarcity of experimental models. The discovery that neurons can be generated from human induced pluripotent stem cells (hiPSCs) paves the way for novel approaches that are stem cell-based. Here, we developed a technique to follow the development of transplanted hiPSC-derived neuronal precursors in the cortex of mice over time. Using post-mortem immunohistochemistry we quantified the differentiation and maturation of dendritic patterns of the human neurons over a total of six months. In addition, entirely hiPSC-derived neuronal parenchyma was followed over eight months using two-photon in vivo imaging through a cranial window. We found that transplanted hiPSC-derived neuronal precursors exhibit a "protracted" human developmental programme in different cortical areas. This offers novel possibilities for the sequential in vivo study of human cortical development and its alteration, followed in "real time".


Subject(s)
Induced Pluripotent Stem Cells/transplantation , Motor Cortex/embryology , Neurogenesis/physiology , Pyramidal Cells/transplantation , Animals , Brain/embryology , Cells, Cultured , Humans , Induced Pluripotent Stem Cells/cytology , Mice , Mice, Inbred NOD , Mice, SCID , Motor Cortex/cytology , Pyramidal Cells/cytology , Transplantation, Heterologous
2.
EMBO Mol Med ; 9(1): 112-132, 2017 01.
Article in English | MEDLINE | ID: mdl-27881461

ABSTRACT

Lysosomal storage disorders (LSDs) are inherited diseases characterized by lysosomal dysfunction and often showing a neurodegenerative course. There is no cure to treat the central nervous system in LSDs. Moreover, the mechanisms driving neuronal degeneration in these pathological conditions remain largely unknown. By studying mouse models of LSDs, we found that neurodegeneration develops progressively with profound alterations in presynaptic structure and function. In these models, impaired lysosomal activity causes massive perikaryal accumulation of insoluble α-synuclein and increased proteasomal degradation of cysteine string protein α (CSPα). As a result, the availability of both α-synuclein and CSPα at nerve terminals strongly decreases, thus inhibiting soluble NSF attachment receptor (SNARE) complex assembly and synaptic vesicle recycling. Aberrant presynaptic SNARE phenotype is recapitulated in mice with genetic ablation of one allele of both CSPα and α-synuclein. The overexpression of CSPα in the brain of a mouse model of mucopolysaccharidosis type IIIA, a severe form of LSD, efficiently re-established SNARE complex assembly, thereby ameliorating presynaptic function, attenuating neurodegenerative signs, and prolonging survival. Our data show that neurodegenerative processes associated with lysosomal dysfunction may be presynaptically initiated by a concomitant reduction in α-synuclein and CSPα levels at nerve terminals. They also demonstrate that neurodegeneration in LSDs can be slowed down by re-establishing presynaptic functions, thus identifying synapse maintenance as a novel potentially druggable target for brain treatment in LSDs.


Subject(s)
HSP40 Heat-Shock Proteins/analysis , Lysosomal Storage Diseases/pathology , Membrane Proteins/analysis , Neurodegenerative Diseases/pathology , Presynaptic Terminals/pathology , alpha-Synuclein/analysis , Animals , Disease Models, Animal , Mice , Proteolysis , SNARE Proteins/metabolism , Synaptic Vesicles/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...